The Inter-agency Task Force (IATF) for the Management of Emerging Infectious Diseases has approved the recommendations on the Covid-19 vaccine clinical trials by Department of Science and Technology (DOST)-led sub-technical working group (TWG) on vaccine development.
Presidential Spokesperson Harry Roque and DOST Secretary Fortunato de la Peña said the sub-TWG on vaccine development, assisted by the Vaccine Expert Panel, has made the following recommendations:
1) The World Health Organization (WHO) Solidarity Trial will be given priority in clinical trial sites. There are two vaccine clinical trials — the independent clinical trials by companies, and the WHO Solidarity Trial. The WHO will be prioritized, but authorities will make sure the companies will not be deprived of trial sites.
2) Vaccine recipients participating in the WHO Solidarity Trial shall be recruited from the top 5-10 barangays reporting high Covid-19 cases, based on the attack rates per 1,000 population of each barangay. The DOH Epidemiology Bureau will monitor the efficacy of the vaccine.
3) Independent trials will be assigned with trial zones, in such a way that there will be no competition in recruiting participants. In case there will be an outbreak in one town, the WHO vaccine team can move the clinical trials there.”
4) The DOST and the Department of the Interior and Local Government (DILG) have agreed LGUs will be involved in the vaccine clinical trials, and there will be close coordination with LGUs for zoning in barangays.
5) There will be alternative modes of follow-up, such as the use of barangay volunteers and utilization of mobile phones, in consideration of the restricted mobility due to the implementation of general community quarantine in some areas.